SCHEDULE 13G/A: Sofinnova Entities Affirm 7.2% Beneficial Stake in Inventiva S.A. Through Amended SEC Filing
Beneficial Ownership Report Amendment
Sofinnova Crossover I SLP and its related entities have filed an amended Schedule 13G, reaffirming their beneficial ownership of 7.2% of Inventiva S.A.'s voting rights as of December 31, 2024.
Summary
- Sofinnova Crossover I SLP (SC), Sofinnova Partners SAS (SP SAS), and members of SC's investment committee (Antoine Papiernik, Cedric Moreau, Kinam Hong, Joseph Anderson, and Jacques Theurillat) are the reporting persons.
- As of December 31, 2024, the reporting persons collectively beneficially own 7,792,307 voting rights in Inventiva S.A.
- This aggregate amount represents 7.2% of the total 108,641,713 voting rights outstanding for Inventiva S.A. as of the same date.
- The reporting persons hold sole voting power over 7,792,307 shares and sole dispositive power over 6,751,746 shares.
- The beneficial ownership includes 6,751,746 Ordinary Shares, which also encompass ordinary shares represented by American Depositary Shares (ADSs).
Sentiment
Score: 5
Explanation: The document is a factual, compliance-driven filing reporting beneficial ownership, thus it carries a neutral sentiment.
Future Outlook
This filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding Inventiva S.A.'s future performance or strategic direction.
Industry Context
This Schedule 13G/A filing indicates a significant, passive investment stake by Sofinnova, a venture capital firm specializing in life sciences, in Inventiva S.A., a French biopharmaceutical company. Such filings are standard disclosures for institutional investors holding more than 5% of a public company's shares, providing transparency on major ownership positions within the biotech and pharmaceutical sectors.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional ownership stake in Inventiva S.A., confirming the continued investment by Sofinnova entities.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires the filing of this statement (beneficial ownership calculation date). |
| 02/14/2025 | Date the Joint Filing Agreement was executed and the Schedule 13G/A was signed. |
Keywords
Inventiva S.A., Sofinnova Crossover I SLP, Sofinnova Partners SAS, Schedule 13G/A, Beneficial Ownership, Voting Rights, SEC Filing, Biotechnology, Pharmaceuticals, Investment Committee
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.